Alphabet’s Isomorphic Labs raises $5B to accelerate drug discovery with AI
Isomorphic Labs Ltd. today announced that it has closed a $5 billion investment led by Greenoaks and Sequoia Capital.
The venture capital firms were joined by more than a half-dozen other backers. The group included Isomorphic parent Alphabet Inc., which made a “significant investment.” The search giant provided the capital through its GV and CapitalG startup funds.
Isomorphic offers a software platform called the Isomorphic Labs Drug Design Engine, or IsoDDE for short. It uses artificial intelligence to speed up several of the tasks involved in developing new medicines. The Alphabet unit says that multiple pharmaceutical companies are already using IsoDDE to power drug discovery programs.
Pathogens such as viruses comprise numerous proteins that each power a different biological process. Drugs work by neutralizing a single, particularly important protein without which the pathogen can’t function. Developing a new drug requires researchers to find a vulnerable protein within a pathogen and then develop a compound that can effectively target it.
The first step of the workflow is mapping out the shape of a target protein. Researchers look for so-called binding pockets, recesses on the protein’s surface to which a drug can be attached. The task is highly complicated because proteins don’t have fixed shapes. Their configuration changes when they interact with other molecules or encounter new environmental conditions, which happens often.
Isomorphic says that IsoDDE speeds up the task of finding binding pockets. When there are no such pockets, it helps researchers develop compounds that cause a target protein to form them.
Once scientists identify a binding pocket, they have to find a way of attaching a drug molecule to it. The pharmaceutical industry searches for such binding mechanisms using a method called FEP. FEP algorithms can be highly hardware-intensive, which makes them costly. Moreover, they often require a detailed, three-dimensional model of a target protein.
The process of creating 3D protein models for FEP algorithms is itself a highly complex task. It requires scientists to freeze a target protein in a crystal and scan it using specialized X-ray equipment.
IsoDDE skips that step of the research workflow. Furthermore, Isomorphic says that the software can generate higher-quality output than FEP algorithms.
“Our drug design engine is generating molecules with unprecedented precision and speed,” said Isomorphic Chief Executive Demis Hassabis. “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials.”
Isomorphic added that it plans to build new bioengineering infrastructure and grow its partner ecosystem.
Image: Isomorphic Labs
A message from John Furrier, co-founder of SiliconANGLE:
Support our mission to keep content open and free by engaging with theCUBE community. Join theCUBE’s Alumni Trust Network, where technology leaders connect, share intelligence and create opportunities.
- 15M+ viewers of theCUBE videos, powering conversations across AI, cloud, cybersecurity and more
- 11.4k+ theCUBE alumni — Connect with more than 11,400 tech and business leaders shaping the future through a unique trusted-based network
Are you an AWS customer? Support SiliconANGLE financially by buying your AWS services from our Marketplace portal page and links: https://siliconangle.com/aws-marketplace/
About SiliconANGLE Media
Founded by tech visionaries John Furrier and Dave Vellante, SiliconANGLE Media has built a dynamic ecosystem of industry-leading digital media brands that reach 15+ million elite tech professionals. Our new proprietary theCUBE AI Video Cloud is breaking ground in audience interaction, leveraging theCUBEai.com neural network to help technology companies make data-driven decisions and stay at the forefront of industry conversations.